Security
Bicara Therapeutics Inc. Common Stock · BCAX
BCAXNASDAQCommon stockCurrentCIK 2023658Updated Oct 22, 2026
BCAX price & chart
Loading TradingView…
NASDAQ:BCAX on TradingView ↗In the news
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
SCHEDULE 13G/A - filed by T. Rowe Price Investment Management, Inc. regarding Bicara Therapeutics Inc.
Entry into a Material Definitive Agreement
Items 1.01, 9.01
4 filing
SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Bicara Therapeutics Inc.
S-8 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 424,688,000Source | 524,173,000Source | 512,243,000Source | 453,587,000Source | — | 553,599,000Source | 478,077,000Source | — | 430,994,000Source | 509,996,000Source | 233,982,000Source |
| Property, Plant and Equipment, NetUSD | 135,000Source | 130,000Source | 362,000Source | 117,000Source | — | 346,000Source | 136,000Source | — | 330,000Source | 155,000Source | 202,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 171,673,000Source | 520,758,000Source | 96,599,000Source | 436,606,000Source | — | 323,462,000Source | 462,065,000Source | — | 96,685,000Source | 489,711,000Source | 230,440,000Source |
| Assets, CurrentUSD | 297,372,000Source | 521,514,000Source | 503,820,000Source | 444,391,000Source | — | 544,915,000Source | 470,754,000Source | — | 422,053,000Source | 502,533,000Source | 231,073,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,205,000Source | 756,000Source | 6,561,000Source | 7,785,000Source | — | 5,162,000Source | 8,689,000Source | — | 7,252,000Source | 12,822,000Source | 633,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,969,000Source | 414,000Source | 1,151,000Source | 2,237,000Source | — | 1,428,000Source | 552,000Source | — | 1,701,000Source | 690,000Source | 613,000Source |
| Other Assets, NoncurrentUSD | 7,795,000Source | 2,115,000Source | 6,910,000Source | 6,842,000Source | — | 6,910,000Source | 6,635,000Source | — | 6,910,000Source | 6,618,000Source | 2,094,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 21,908,000Source | 14,618,000Source | 43,475,000Source | 18,391,000Source | — | 39,641,000Source | 19,120,000Source | — | 29,542,000Source | 18,121,000Source | 15,474,000Source |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 8,000Source | 7,000Source | — | 8,000Source | 7,000Source | — | 7,000Source | 7,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 724,489,000Source | 709,607,000Source | 939,940,000Source | 720,439,000Source | — | 929,370,000Source | 716,812,000Source | — | 760,168,000Source | 712,884,000Source | 4,250,000Source |
| Retained Earnings (Accumulated Deficit)USD | -321,580,000Source | -200,059,000Source | -470,613,000Source | -285,250,000Source | — | -415,177,000Source | -257,862,000Source | — | -358,966,000Source | -221,016,000Source | -153,021,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -136,000Source | — | -567,000Source | — | — | -243,000Source | — | — | 243,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 402,780,000Source | 509,555,000Source | 468,768,000Source | 435,196,000Source | -174,776,000Source | 513,958,000Source | 458,957,000Source | -160,080,000Source | 401,452,000Source | 491,875,000Source | -148,769,000Source |
| Liabilities and EquityUSD | 424,688,000Source | 524,173,000Source | 512,243,000Source | 453,587,000Source | — | 553,599,000Source | 478,077,000Source | — | 430,994,000Source | 509,996,000Source | 233,982,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 21,028,000Source | 14,481,000Source | 43,475,000Source | 17,227,000Source | — | 39,340,000Source | 19,120,000Source | — | 28,949,000Source | 17,990,000Source | 15,085,000Source |
| Operating Lease, Liability, CurrentUSD | 1,095,000Source | 308,000Source | 1,163,000Source | 1,074,000Source | — | 1,140,000Source | 591,000Source | — | 1,117,000Source | 607,000Source | 285,000Source |
| Operating Lease, Liability, NoncurrentUSD | 880,000Source | 137,000Source | 0Source | 1,164,000Source | — | 301,000Source | 0Source | — | 593,000Source | 131,000Source | 372,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | — | — | — | — | — | — | — | 0Source | 17,000Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | 12,875,000Source | 8,053,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 414,800,000Source | — | — |
| Short-term InvestmentsUSD | 118,494,000Source | — | — | — | — | — | — | — | 318,116,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,858,000Source | 3,451,000Source | 15,006,000Source | 7,397,000Source | 1,899,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -37,508,000Source | -28,106,000Source | -106,834,000Source | -74,751,000Source | -45,628,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 100,940,000Source | 0Source | -318,453,000Source | -9,000Source | -586,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 60,000Source | 0Source | 280,000Source | 71,000Source | 586,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 163,345,000Source | 460,000Source | 32,261,000Source | 334,031,000Source | 272,496,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 226,777,000Source | -27,646,000Source | -393,026,000Source | 259,271,000Source | 226,282,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 171,673,000Source | 520,758,000Source | 96,599,000Source | 436,606,000Source | 323,462,000Source | 462,065,000Source | 96,685,000Source | 489,711,000Source | 230,440,000Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,614,000Source | 2,031,000Source | 8,238,000Source | 3,492,000Source | 5,858,000Source | 3,451,000Source | 15,006,000Source | 7,397,000Source | 1,899,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 414,800,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 44,000Source | 19,000Source | 105,000Source | 56,000Source | 19,000Source |
| General and Administrative ExpenseUSD | — | — | 7,701,000Source | 4,764,000Source | 14,178,000Source | 7,220,000Source | 12,742,000Source | 7,455,000Source | 30,508,000Source | 18,770,000Source | 9,272,000Source |
| Income Tax Expense (Benefit)USD | — | — | 40,000Source | 0Source | 61,000Source | 52,000Source | 52,000Source | 72,000Source | 217,000Source | 180,000Source | 5,000Source |
| Investment Income, InterestUSD | — | — | 4,386,000Source | 3,147,000Source | 4,576,000Source | 4,682,000Source | 4,083,000Source | 5,014,000Source | 17,871,000Source | 14,581,000Source | 1,314,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -36,330,000Source | -17,481,000Source | -55,436,000Source | -27,388,000Source | -56,211,000Source | -36,846,000Source | -137,950,000Source | -67,995,000Source | -51,985,000Source |
| Nonoperating Income (Expense)USD | — | — | 4,386,000Source | 3,147,000Source | 4,576,000Source | 4,682,000Source | 4,083,000Source | 5,014,000Source | 17,871,000Source | 14,581,000Source | -12,091,000Source |
| Operating ExpensesUSD | — | — | 40,676,000Source | 20,628,000Source | 59,951,000Source | 32,018,000Source | 60,242,000Source | 41,788,000Source | 155,604,000Source | 82,389,000Source | 39,889,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 318,173,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 161,763,000Source | 0Source | 29,498,000Source | 332,427,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,582,000Source | 460,000Source | 2,763,000Source | 1,604,000Source | 149,000Source |
| Operating Lease, Expense | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -40,676,000Source | -20,628,000Source | -59,951,000Source | -32,018,000Source | -60,242,000Source | -41,788,000Source | -155,604,000Source | -82,389,000Source | -39,889,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -36,290,000Source | -17,481,000Source | -55,375,000Source | -27,336,000Source | -56,159,000Source | -36,774,000Source | -137,733,000Source | -67,808,000Source | -51,980,000Source |
| Income Tax Expense (Benefit)USD | — | — | 40,000Source | 0Source | 61,000Source | 52,000Source | 52,000Source | 72,000Source | 217,000Source | 180,000Source | 5,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -36,330,000Source | -17,481,000Source | -55,436,000Source | -27,388,000Source | -56,211,000Source | -36,846,000Source | -137,950,000Source | -67,995,000Source | -51,985,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.67Source | -1.6Source | -0.82Source | -0.5Source | -0.93Source | -0.68Source | -2.52Source | -4.05Source | -89.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.67Source | -1.6Source | -0.82Source | -0.5Source | -0.93Source | -0.68Source | -2.52Source | -4.05Source | -89.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 54,563,864Source | 10,901,138Source | 67,925,963Source | 54,539,230Source | 60,717,041Source | 54,456,515Source | 54,676,896,000Source | 16,805,524,000Source | 580,109,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 54,563,864Source | 10,901,138Source | 67,925,963Source | 54,539,230Source | 60,717,041Source | 54,456,515Source | 54,676,896,000Source | 16,805,524,000Source | 580,109,000Source |
| Additional Financial Items | |||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 217,000Source | 180,000Source | 5,000Source |
| General and Administrative ExpenseUSD | — | — | 7,701,000Source | 4,764,000Source | 14,178,000Source | 7,220,000Source | 12,742,000Source | 7,455,000Source | 30,508,000Source | 18,770,000Source | 9,272,000Source |
| Investment Income, InterestUSD | — | — | 4,386,000Source | 3,147,000Source | 4,576,000Source | 4,682,000Source | 4,083,000Source | 5,014,000Source | 17,871,000Source | 14,581,000Source | 1,314,000Source |
| Nonoperating Income (Expense)USD | — | — | 4,386,000Source | 3,147,000Source | 4,576,000Source | 4,682,000Source | 4,083,000Source | 5,014,000Source | 17,871,000Source | 14,581,000Source | -12,091,000Source |
| Operating ExpensesUSD | — | — | 40,676,000Source | 20,628,000Source | 59,951,000Source | 32,018,000Source | 60,242,000Source | 41,788,000Source | 155,604,000Source | 82,389,000Source | 39,889,000Source |
| Research and Development ExpenseUSD | — | — | 33,000,000Source | 15,900,000Source | — | 24,800,000Source | — | 34,300,000Source | — | 63,600,000Source | 30,600,000Source |
| Operating Lease, Expense | — | — | — | — | — | —Source | — | — | — | — | — |
Filing attachments
d938194dex41.htm · 8-K · 2026-02-26
EX-4.1 3 d938194dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 BICARA THERAPEUTICS INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [__] (subject to adjustment) Warrant No. [__] Original Issue Date: February [26], 2026 Bicara Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [____] or its registered assigns (the “Holder”) is entitl…
Read attachment ↗d904889dex991.htm · 8-K · 2025-01-13
EX-99.1 2 d904889dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Fighting cancer with precision and power. Corporate Presentation | January 2025 © 2024 - 2025 Bicara Therapeutics Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding our product development activities for ficerafusp alf…
Read attachment ↗